APA (7th ed.) Citation

Hoster, E., Unterhalt, M., Hänel, M., Prange ‐ Krex, G., Forstpointner, R., Florschütz, A., . . . Hiddemann, W. (2017). RITUXIMAB MAINTENANCE VERSUS OBSERVATION AFTER IMMUNOCHEMOTHERAPY (R-CHOP, R-MCP, R-FCM) IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RANDOMISED TRIAL OF GLSG AND OSHO. Hematological oncology, 35, 32. https://doi.org/10.1002/hon.2437_12

Chicago Style (17th ed.) Citation

Hoster, E., et al. "RITUXIMAB MAINTENANCE VERSUS OBSERVATION AFTER IMMUNOCHEMOTHERAPY (R-CHOP, R-MCP, R-FCM) IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RANDOMISED TRIAL OF GLSG AND OSHO." Hematological Oncology 35 (2017): 32. https://doi.org/10.1002/hon.2437_12.

MLA (9th ed.) Citation

Hoster, E., et al. "RITUXIMAB MAINTENANCE VERSUS OBSERVATION AFTER IMMUNOCHEMOTHERAPY (R-CHOP, R-MCP, R-FCM) IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RANDOMISED TRIAL OF GLSG AND OSHO." Hematological Oncology, vol. 35, 2017, p. 32, https://doi.org/10.1002/hon.2437_12.